| scholarly article | Q13442814 |
| P50 | author | Albrecht Reichle | Q59819086 |
| P2093 | author name string | U Schulz | |
| R Andreesen | |||
| F Klebl | |||
| W Herr | |||
| R Wiest | |||
| I Walter | |||
| L Ghibelli | |||
| E Endlicher | |||
| C Hackl | |||
| M Vogelhuber | |||
| K Wiedmann | |||
| P2860 | cites work | Global cancer statistics, 2012 | Q27860501 |
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis | Q28067391 | ||
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 | ||
| Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells | Q33284848 | ||
| Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway | Q33554975 | ||
| Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma | Q33618658 | ||
| Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. | Q33688897 | ||
| Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. | Q34483561 | ||
| Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression | Q35543448 | ||
| PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. | Q35927161 | ||
| Serum C-reactive protein levels predict survival in hepatocellular carcinoma | Q81226961 | ||
| Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats | Q83304890 | ||
| Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors | Q83710870 | ||
| Management of hand-foot syndrome induced by capecitabine | Q36615314 | ||
| Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis | Q36746912 | ||
| Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer? | Q37018002 | ||
| Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma | Q37031730 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma. | Q37209921 | ||
| Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma | Q37236004 | ||
| Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies | Q37263149 | ||
| Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study | Q37404372 | ||
| Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety | Q38160838 | ||
| Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells | Q38306392 | ||
| CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth | Q38319523 | ||
| Systemic treatment for hepatocellular carcinoma: Still unmet expectations | Q39112745 | ||
| Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials | Q39113725 | ||
| Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. | Q39698351 | ||
| Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells | Q40249987 | ||
| Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. | Q40372701 | ||
| Expression of peroxisome proliferator-activated receptor delta in human gastric cancer and its response to specific COX-2 inhibitor. | Q40423550 | ||
| Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia | Q40640442 | ||
| MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition | Q40990148 | ||
| Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study | Q41621514 | ||
| Systems biology: a therapeutic target for tumor therapy | Q41961938 | ||
| Principles of modular tumor therapy | Q42053204 | ||
| C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation | Q42590411 | ||
| Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study | Q43938501 | ||
| Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. | Q44656367 | ||
| Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. | Q47293605 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 192 | |
| P577 | publication date | 2017-11-02 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial | |
| P478 | volume | 34 |
| Q64118821 | A Computational Model of Tumor Growth and Anakoinosis |
| Q92541944 | Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction |
| Q59805381 | Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis |
| Q64070822 | Exosomes and Hepatocellular Carcinoma: From Bench to Bedside |
| Q59335637 | Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction |
| Q59793687 | Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue |
Search more.